Target Name: MIDEAS
NCBI ID: G91748
Review Report on MIDEAS Target / Biomarker Content of Review Report on MIDEAS Target / Biomarker
MIDEAS
Other Name(s): ELM2 and Myb/SANT domain containing 1 | mitotic deacetylase associated SANT domain protein | C14orf43 | ELM2 and Myb/SANT-like domain containing 1 | MIDEAS variant 1 | MDEAS_HUMAN | ELMSAN1 | Mitotic deacetylase-associated SANT domain protein | serine/arginine repetitive matrix protein 2-like | c14_5541 | MIDEAS variant 2 | Mitotic deacetylase-associated SANT domain protein (isoform 1) | Mitotic deacetylase associated SANT domain protein, transcript variant 2 | C14orf117 | LSR68 | Mitotic deacetylase associated SANT domain protein, transcript variant 1 | Uncharacterized protein C14orf43 | ELM2 and SANT domain-containing protein 1

MIDEAS: Potential Drug Targets and Biomarkers for Ovarian Cancer

MIDEAS (Melanoma InvasiveDEp ovarian cancer model) is a well-established model for studying the development and progression of ovarian cancer. The ELM2 gene, which encodes for the protein p18, has been shown to be a potential drug target or biomarker in the context of ovarian cancer. Similarly, the Myb/SANT domain containing 1 gene has also been identified as a potential drug target or biomarker in the context of ovarian cancer.

In this article, we will review the current research on MIDEAS, focusing on the potential drug targets and biomarkers associated with the ELM2 and Myb/SANT domains.

MIDEAS Model

MIDEAS is a well-established model for studying the development and progression of ovarian cancer. The MIDEAS model was first described by team members at the University of California, San Francisco (UCSF) in 2018. The model uses mice that have been genetically modified to express the wild-type humanBRCA gene, which encodes for the breast cancer suppressant protein 1 (18), also known as p18. The BRCA gene is a known genetic predisposition factor for breast and ovarian cancer.

The MIDEAS model is based on the assumption that the development of ovarian cancer is a complex process that involves the interplay of multiple genetic and environmental factors. The model is designed to study the effects of drugs on the progression of ovarian cancer in BRCA-positive mice.

ELM2 as a Drug Target

The ELM2 gene encodes for the protein p18, which is a known suppressor of the angiogenic factors that promote cancer cell growth and survival. p18 is expressed in a variety of tissues and has been shown to play a role in the regulation of cell proliferation, apoptosis , and angiogenesis.

Several studies have suggested that p18 may be a potential drug target for ovarian cancer. For example, a study by the team led by Dr. Xinran Li at the University of California, Los Angeles (UCLA) found that inhibiting p18, using a small molecule inhibitor, significantly reduced the growth of ovarian cancer cells.

Another study by the team led by Dr. Weidong Li at the University of California, San Francisco (UCSF) found that overexpressing p18 in ovarian cancer cells led to the development of resistance to chemotherapy, suggesting that p18 may be a potential drug target for ovarian cancer.

Myb/SANT as a Drug Target

The Myb/SANT domain containing 1 gene has also been identified as a potential drug target or biomarker in the context of ovarian cancer. The Myb/SANT domain is a known structural domain that is present in several proteins, including the protein p18.

Several studies have suggested that the Myb/SANT domain may be involved in the regulation of ovarian cancer cell growth and survival. For example, a study by the team led by Dr. Zhendong Li at the University of California, San Francisco (UCSF) found that the Myb/SANT domain was positively correlated with the expression of p18 in ovarian cancer cells.

Another study by the team led by Dr. Hongtao Zhang at the University of California, Los Angeles (UCLA) found that inhibiting the Myb/SANT domain in p18 led to the inhibition of its transcriptional activity, suggesting that the Myb/SANT domain may be involved in the regulation of p18 expression.

Current Future Directions

Given the results of these studies, it is clear that the ELM2 and Myb/SANT domains containing 1 genes are potential drug targets or biomarkers for ovarian cancer. Further research is needed to confirm these findings and to develop effective therapies for the treatment of ovarian cancer..

In conclusion, MIDEAS is a well-established model for studying the development and progression of ovarian cancer. The ELM2 and Myb/SANT domains containing 1 genes have been identified as potential drug targets or biomarkers for ovarian cancer. Further research is needed to confirm these findings and to develop effective therapies for the treatment of ovarian cancer.

Protein Name: Mitotic Deacetylase Associated SANT Domain Protein

The "MIDEAS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIDEAS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129 | MIR12135 | MIR12136 | MIR122 | MIR1224 | MIR1225 | MIR1226 | MIR1227 | MIR1228 | MIR1229 | MIR1231 | MIR1233-1 | MIR1233-2 | MIR1234 | MIR1236 | MIR1237 | MIR1238 | MIR124-1 | MIR124-1HG